Glycomine received FTD for GLM101 Glycomine, Inc. has received FDA Fast Track Designation for GLM101, a mannose-1-phosphate replacement therapy aimed at treating phosphomannomutase 2-congenital disorder of glycosylation...
MannKind Corporation has announced clearance from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to begin the Phase 3 clinical trial (ICoN-1) of its Clofazimine Inhalation Suspension for treating nontuberculous...
Glycomine received FTD for GLM101 Glycomine, Inc. has received FDA Fast Track Designation for GLM101, a mannose-1-phosphate replacement therapy aimed at treating phosphomannomutase 2-congenital disorder of glycosylation...
